Nevertheless, the full spectrum of breast/ovarian cancer susceptibility genes has not yet been identified, but several of them with strong evidence including CHEK2 (checkpoint kinase 2 gene), ATM (ataxia–telangiectasia mutated gene), TP53 (tumor protein p53 gene), PALB2 (partner and localiser of BRCA2 gene), PTEN (phosphatase and tensin homolog gene), and NBN (Nijmegen breakage syndrome gene) are considered in screening for hereditary predispositions of those cancers [7]. This evidence concerns the gene TP53 and ovarian carcinoma.